financetom
Business
financetom
/
Business
/
Aya Gold & Silver Swings to Q3 Earnings as Revenue Soars 393%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Aya Gold & Silver Swings to Q3 Earnings as Revenue Soars 393%
Nov 11, 2025 5:00 AM

07:41 AM EST, 11/11/2025 (MT Newswires) -- Aya Gold & Silver ( AYASF ) swung to net earnings following a 393% surge in revenue for the third quarter.

The miner reported a net income of US$12.4 million, or $0.09 per share, compared to a year-ago loss of $263,000, or a loss of nil per share, and in line with the analyst consensus forecast of $0.09 per share compiled by FactSet.

Revenue climbed to $54.3 million from $11.0 million, above the analyst consensus estimate of $52.7 million compiled by Factset.

Aya said the revenue increase reflects the successful start of commercial production of the new Zgounder plant in Morocco in December 2024 and a 46% jump in the average net realized silver price to $39.85 per ounce.

Aya reported record silver production of 1.35 million ounces, up 278% from the prior year, driven by the new Zgounder plant.

"The ramp-up at Zgounder is nearly complete, and the mill is now running at a steady state," President and Chief Executive Officer Benoit La Salle said. "We are seeing improvements and continue to make targeted improvements to the mine plan, with a focus on optimizing grade control and minimizing dilution."

Aya's share price gained 6.9% on Monday to C$15.27 on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Is Immuno-Oncology Focused Aptevo Therapeutics Stock Trading Higher On Thursday?
Why Is Immuno-Oncology Focused Aptevo Therapeutics Stock Trading Higher On Thursday?
Mar 7, 2024
Thursday, Alligator Bioscience AB and Aptevo Therapeutics Inc ( APVO ) released interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for solid tumors likely to express the tumor antigen 5T4. The multi-center, dose-escalation trial is now more than 50% enrolled, and preliminary results include: Treatment was overall well-tolerated, and a maximum tolerated dose has not yet been determined. Dose...
Top Midday Gainers
Top Midday Gainers
Mar 7, 2024
01:51 PM EST, 03/07/2024 (MT Newswires) -- Lytus Technologies' (LYT) shares more than quadrupled amid heavy trading after the company unveiled late Thursday the launch of its suite of cloud infrastructure services. Shares catapulted 357% as intraday trading volume soared to over 66.9 million from a daily average of about 260,000. Immuron ( IMRN ) said Thursday that interim topline...
Albemarle Unusual Options Activity
Albemarle Unusual Options Activity
Mar 7, 2024
Investors with a lot of money to spend have taken a bullish stance on Albemarle . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALB,...
EV maker Rivian unveils smaller, less expensive SUVs, crossovers
EV maker Rivian unveils smaller, less expensive SUVs, crossovers
Mar 7, 2024
LAGUNA BEACH, California (Reuters) -Rivian on Thursday unveiled its smaller and less expensive R2 SUVs and R3 crossovers amid a slowdown in demand for EVs and also said it would start producing the R2 at its existing facility in Illinois to ensure deliveries in 2026. Rivian shares were up 10% at $12.16 on Thursday afternoon. The R2, with a starting...
Copyright 2023-2026 - www.financetom.com All Rights Reserved